| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 681 | 2018 |
| Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor JM Lin, AS Lalani, TC Harding, M Gonzalez, WW Wu, B Luan, GH Tu, ... Cancer research 65 (15), 6901-6909, 2005 | 338 | 2005 |
| The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues KA Graham, AS Lalani, JL Macen, TL Ness, M Barry, LY Liu, A Lucas, ... Virology 229 (1), 12-24, 1997 | 272 | 1997 |
| Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF–secreting cancer immunotherapy B Li, AS Lalani, TC Harding, B Luan, K Koprivnikar, G Huan Tu, R Prell, ... Clinical Cancer Research 12 (22), 6808-6816, 2006 | 266 | 2006 |
| Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition C Daly, A Eichten, C Castanaro, E Pasnikowski, A Adler, AS Lalani, ... Cancer research 73 (1), 108-118, 2013 | 247 | 2013 |
| The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines AS Lalani, K Graham, K Mossman, K Rajarathnam, I Clark-Lewis, ... Journal of virology 71 (6), 4356-4363, 1997 | 226 | 1997 |
| Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer CX Ma, R Bose, F Gao, RA Freedman, ML Telli, G Kimmick, E Winer, ... Clinical Cancer Research 23 (19), 5687-5695, 2017 | 200 | 2017 |
| Use of chemokine receptors by poxviruses AS Lalani, J Masters, W Zeng, J Barrett, R Pannu, H Everett, CW Arendt, ... Science 286 (5446), 1968-1971, 1999 | 194 | 1999 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 180 | 2020 |
| Immunomodulation by viruses: the myxoma virus story P Nash, J Barrett, JX Cao, S Hota‐Mitchell, AS Lalani, H Everett, XM Xu, ... Immunological reviews 168 (1), 103-120, 1999 | 172 | 1999 |
| Modulating chemokines: more lessons from viruses AS Lalani, JW Barrett, G McFadden Immunology today 21 (2), 100-106, 2000 | 167 | 2000 |
| Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study MR Albertella, PM Loadman, PH Jones, RM Phillips, R Rampling, ... Clinical cancer research 14 (4), 1096-1104, 2008 | 151 | 2008 |
| C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer: results from the ASCENT trial TM Beer, AS Lalani, S Lee, M Mori, KM Eilers, JG Curd, WD Henner, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 122 | 2008 |
| The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury L Liu, A Lalani, E Dai, B Seet, C Macauley, R Singh, L Fan, G McFadden, ... The Journal of clinical investigation 105 (11), 1613-1621, 2000 | 117 | 2000 |
| Interruption of cytokine networks by poxviruses: lessons from myxoma virus G McFadden, K Graham, K Ellison, M Barry, J Macen, M Schreiber, ... Journal of leukocyte biology 57 (5), 731-738, 1995 | 112 | 1995 |
| Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer LM Smyth, SA Piha-Paul, HH Won, AM Schram, C Saura, S Loi, J Lu, ... Cancer discovery 10 (2), 198-213, 2020 | 108 | 2020 |
| Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis A Nagpal, RP Redvers, X Ling, S Ayton, M Fuentes, E Tavancheh, I Diala, ... Breast Cancer Research 21, 1-19, 2019 | 108 | 2019 |
| Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer S Croessmann, L Formisano, LN Kinch, PI Gonzalez-Ericsson, ... Clinical Cancer Research 25 (1), 277-289, 2019 | 107 | 2019 |
| An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer AB Hanker, MR Brewer, JH Sheehan, JP Koch, GR Sliwoski, R Nagy, ... Cancer discovery 7 (6), 575-585, 2017 | 100 | 2017 |
| Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis AS Lalani, J Masters, K Graham, L Liu, A Lucas, G McFadden Virology 256 (2), 233-245, 1999 | 96 | 1999 |
